CMA issues charges in second pay-for-delay case
Credit: iStock/DanielAzocar
The UK’s competition authority has accused two pharmaceutical companies of entering anticompetitive agreements that boosted prices the country’s National Health Service paid for anti-inflammatory drug hydrocortisone
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now